Wedge Capital Management L L P NC Sells 967 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Wedge Capital Management L L P NC trimmed its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 0.4% during the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 223,918 shares of the biopharmaceutical company’s stock after selling 967 shares during the period. Wedge Capital Management L L P NC owned about 0.08% of Amicus Therapeutics worth $3,177,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently bought and sold shares of the company. Duality Advisers LP boosted its position in Amicus Therapeutics by 56.1% in the 4th quarter. Duality Advisers LP now owns 26,763 shares of the biopharmaceutical company’s stock valued at $380,000 after buying an additional 9,619 shares during the last quarter. Handelsbanken Fonder AB boosted its position in shares of Amicus Therapeutics by 13.0% in the 4th quarter. Handelsbanken Fonder AB now owns 54,041 shares of the biopharmaceutical company’s stock worth $767,000 after purchasing an additional 6,200 shares during the last quarter. HealthInvest Partners AB bought a new position in shares of Amicus Therapeutics in the 4th quarter worth $691,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Amicus Therapeutics by 15.0% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 48,674 shares of the biopharmaceutical company’s stock worth $691,000 after purchasing an additional 6,347 shares during the last quarter. Finally, Mackenzie Financial Corp boosted its position in shares of Amicus Therapeutics by 17.2% in the 4th quarter. Mackenzie Financial Corp now owns 29,057 shares of the biopharmaceutical company’s stock worth $412,000 after purchasing an additional 4,260 shares during the last quarter.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the company. JPMorgan Chase & Co. reduced their price target on Amicus Therapeutics from $21.00 to $19.00 and set an “overweight” rating on the stock in a research report on Monday, March 18th. Cantor Fitzgerald restated an “overweight” rating and issued a $22.00 price target on shares of Amicus Therapeutics in a research report on Thursday, February 29th.

Amicus Therapeutics Stock Performance

Shares of Amicus Therapeutics stock opened at $10.54 on Thursday. The company has a market capitalization of $3.11 billion, a PE ratio of -20.67 and a beta of 0.75. Amicus Therapeutics, Inc. has a 12 month low of $9.70 and a 12 month high of $14.57. The company has a current ratio of 2.88, a quick ratio of 2.52 and a debt-to-equity ratio of 2.42. The stock’s fifty day simple moving average is $12.08 and its 200 day simple moving average is $12.01.

Amicus Therapeutics (NASDAQ:FOLD) last issued its quarterly earnings data on Wednesday, February 28th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.05). Amicus Therapeutics had a negative return on equity of 119.46% and a negative net margin of 37.96%. The business had revenue of $115.08 million for the quarter, compared to analyst estimates of $115.11 million. On average, research analysts predict that Amicus Therapeutics, Inc. will post 0.01 EPS for the current year.

Insider Buying and Selling at Amicus Therapeutics

In other Amicus Therapeutics news, Director Margaret G. Mcglynn sold 7,500 shares of Amicus Therapeutics stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $13.40, for a total value of $100,500.00. Following the sale, the director now owns 59,289 shares of the company’s stock, valued at approximately $794,472.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other Amicus Therapeutics news, Director Margaret G. Mcglynn sold 7,500 shares of Amicus Therapeutics stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $13.40, for a total value of $100,500.00. Following the sale, the director now owns 59,289 shares of the company’s stock, valued at approximately $794,472.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Bradley L. Campbell sold 4,167 shares of Amicus Therapeutics stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $14.00, for a total value of $58,338.00. Following the completion of the sale, the chief executive officer now directly owns 871,219 shares in the company, valued at approximately $12,197,066. The disclosure for this sale can be found here. Insiders have sold 48,108 shares of company stock valued at $662,605 in the last 90 days. 2.10% of the stock is currently owned by company insiders.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.